Quick Answer
TENAX THERAPEUTICS, INC. reported Total Revenue of $0.00 for fiscal year 2016.
TENAX THERAPEUTICS, INC. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Total Revenue | — | — | — | — | — | — |
| Net Income | -$52.60M -198.8% |
-$17.60M -128.3% |
-$7.71M -169.8% |
$11.05M +134.0% |
-$32.47M -229.6% |
-$9.85M -17.4% |
| Diluted EPS | -$1.34 -16.5% |
-$1.15 +96.3% |
-$31.04 | — | — | — |
| Total Assets | $104.23M +7.8% |
$96.69M +727.4% |
$11.69M +243.2% |
$3.40M -43.2% |
$5.99M -12.8% |
$6.87M +7.9% |
| Cash and Equivalents | — | — | — | $2.12M -62.0% |
$5.58M -10.7% |
$6.25M +27.4% |
| Stockholders Equity | $97.07M +5.5% |
$91.99M +1036.0% |
$8.10M +442.4% |
$1.49M -64.8% |
$4.24M -8.2% |
$4.63M +22.6% |
| R&D Expense | $32.67M +157.1% |
$12.71M +293.6% |
$3.23M -40.0% |
$5.38M -78.6% |
$25.15M +451.4% |
$4.56M +31.4% |
| Operating Income | -$56.38M -189.2% |
-$19.49M -136.8% |
-$8.23M -174.5% |
$11.05M +133.8% |
-$32.73M -431.7% |
$9.87M +215.3% |
| Gross Profit | — | — | — | — | — | — |
| Shares Outstanding | 9.31M +172.3% |
3.42M +1046.9% |
298,281 +941.2% |
28,648 -97.7% |
1.26M -90.0% |
12.62M +87.2% |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | January 31, 2015 | $0.00 | -100.0% | — |
| Net Income | September 30, 2025 | -$15.80M | -299.0% | -45.7% |
| Diluted EPS | September 30, 2025 | -$0.40 | -110.5% | -48.1% |
| Total Assets | September 30, 2025 | $102.81M | +3.0% | -2.9% |
| Cash and Equivalents | June 30, 2023 | $13.39M | +85.3% | -7.1% |
| Stockholders Equity | September 30, 2025 | $96.21M | -1.0% | -6.9% |
| R&D Expense | September 30, 2025 | $10.33M | +231.9% | +68.7% |
| Operating Income | September 30, 2025 | -$16.81M | -263.8% | -42.5% |
| Gross Profit | January 31, 2015 | $0.00 | -100.0% | — |
| Shares Outstanding | September 30, 2025 | 5.91M | +73.3% | +42.4% |
- TENAX THERAPEUTICS, INC. reported Total Revenue of $0.00 for fiscal year 2016.
- TENAX THERAPEUTICS, INC. showed a decrease of -100.0% in Total Revenue compared to the prior fiscal year.
- TENAX THERAPEUTICS, INC. reported Net Income of -$52.60 million for fiscal year 2025.
- TENAX THERAPEUTICS, INC. showed a decrease of -198.8% in Net Income compared to the prior fiscal year.
- TENAX THERAPEUTICS, INC. reported Diluted EPS of $1.34 per share (loss) for fiscal year 2025.
- TENAX THERAPEUTICS, INC. showed a decrease of -16.5% in Diluted EPS compared to the prior fiscal year.
- TENAX THERAPEUTICS, INC. reported Total Assets of $104.23 million for fiscal year 2025.
- TENAX THERAPEUTICS, INC. showed an increase of +7.8% in Total Assets compared to the prior fiscal year.
- TENAX THERAPEUTICS, INC. reported Cash and Equivalents of $2.12 million for fiscal year 2022.
- TENAX THERAPEUTICS, INC. showed a decrease of -62.0% in Cash and Equivalents compared to the prior fiscal year.
- TENAX THERAPEUTICS, INC. reported Stockholders Equity of $97.07 million for fiscal year 2025.
- TENAX THERAPEUTICS, INC. showed an increase of +5.5% in Stockholders Equity compared to the prior fiscal year.
- TENAX THERAPEUTICS, INC. reported R&D Expense of $32.67 million for fiscal year 2025.
- TENAX THERAPEUTICS, INC. showed an increase of +157.1% in R&D Expense compared to the prior fiscal year.
- TENAX THERAPEUTICS, INC. reported Operating Income of -$56.38 million for fiscal year 2025.
- TENAX THERAPEUTICS, INC. showed a decrease of -189.2% in Operating Income compared to the prior fiscal year.
- TENAX THERAPEUTICS, INC. reported Gross Profit of $0.00 for fiscal year 2016.
- TENAX THERAPEUTICS, INC. reported Shares Outstanding of 9.31 million shares for fiscal year 2025.
- TENAX THERAPEUTICS, INC. showed an increase of +172.3% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: